Lannett says it is satisfied with its reported sales of $144.4m for the third quarter of its financial year ending in June 2020, despite this representing a 16.4% drop compared to the $172.8m reported for the third quarter of fiscal 2019.
CEO Tim Crew explained that after losing the distribution deal for highly profitable thyroid drug levothyroxine – when former partner...




